Centre to amend law to reduce delays in drug development, approval process

/2 min read

ADVERTISEMENT

The amendments will also enable the central drug regulator—Central Drugs Standard Control Organisation (CDSCO)—to optimise the deployment of its human resources, thereby enhancing the efficiency and effectiveness of regulatory oversight.
Centre to amend law to reduce delays in drug development, approval process
As part of simplifying the requirements and procedures for obtaining test licences, the proposed amendment seeks to convert the present system for issuing test licences into a notification/intimation system.  

The Union Health Ministry is planning to amend the New Drugs and Clinical Trials (NDCT) Rules, 2019, to reduce the delays in the drug development and approval processes in India. The amendments are intended to facilitate the quicker initiation of bioavailability and bioequivalence (BA/BE) studies, which test and examine drugs for research purposes in the country.

As part of simplifying the requirements and procedures for obtaining test licences, the proposed amendment seeks to convert the present system for issuing test licences into a notification/intimation system. It is expected that the change will permit applicants to avoid the wait to obtain test licenses from the drug regulatory authority, allowing them to proceed with their plans after notifying the Central Licensing Authority. A small category of high-risk category drugs will still need to obtain this approval, though the amendment will see the overall statutory processing time for test licence applications reduced from 90 days to 45 days.

Similarly, the amendment will also see the existing licence requirement getting dispensed with for certain categories of BA/BE studies, which may instead be initiated upon submission of an intimation or notification to the Central Licensing Authority.

These regulatory reforms are expected to benefit stakeholders by significantly reducing the timelines for processing applications. According to the ministry, the proposed amendments will reduce the number of license applications submitted by approximately 50% and facilitate the quicker initiation of BA/BE studies, testing, and examination of drugs for research, thereby reducing delays in the drug development and approval processes.

Fortune India Latest Edition is Out Now!
India's Top 100 Billionaires

August 2025

As India continues to be the world’s fastest-growing major economy, Fortune India presents its special issue on the nation’s Top 100 Billionaires. Curated in partnership with Waterfield Advisors, this year’s list reflects a slight decline in the number of dollar billionaires—from 185 to 182—even as the entry threshold for the Top 100 rose to ₹24,283 crore, up from ₹22,739 crore last year. From stalwarts like Mukesh Ambani, Gautam Adani, and the Mistry family, who continue to lead the list, to major gainers such as Sunil Mittal and Kumar Mangalam Birla, the issue goes beyond the numbers to explore the resilience, ambition, and strategic foresight that define India’s wealth creators. Read their compelling stories in the latest issue of Fortune India. On stands now.

Read Now

The amendments will also enable the central drug regulator—Central Drugs Standard Control Organisation (CDSCO)—to optimise the deployment of its human resources, thereby enhancing the efficiency and effectiveness of regulatory oversight.

The ministry showcases the proposed amendment as the Government’s commitment to ongoing regulatory reforms in the pharmaceutical sector.

“It forms a part of the broader efforts toward Ease of Doing Business to promote the growth of the Indian pharma industry and align domestic regulations with global best practices. These steps are expected to increase the attractiveness of India for clinical research, thereby strengthening India’s position as a global hub for pharmaceutical research and development”, a health ministry statement said.

Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.